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Abstract
Duchenne muscular dystrophy (DMD) is a neuromuscular disorder caused by dystrophin
loss—notably within muscles and CNS neurons. DMD presents as cognitive weakness,
progressive skeletal and cardiac muscle degeneration until pre-mature death from cardiac or
respiratory failure. Innovative therapies improved life expectancy, but this is accompanied by
increased late-onset heart failure and emergent cognitive degeneration. Thus, there is an
increasing need to both better understand and track disease pathophysiology in the dystrophic
heart and brain prior to onset of severe degenerative symptoms. Chronic inflammation is strongly
associated with skeletal and cardiac muscle degeneration, however chronic neuroinflammation’s
role is largely unknown in DMD despite being prevalent in other neurodegenerative diseases.
Considering the well-known consequences of unchecked chronic inflammation, inflammation’s
contribution towards multi-organ degeneration must be explored. Thus, this study explored
inflammatory marker translocator protein positron emission tomography (TSPO-PET) to
evaluate immune cell infiltration within the hearts and brains of DMD murine models. Four
DMD and six healthy mice underwent whole-body PET imaging using the TSPO radiotracer
[18F]FEPPA. Confirmatory TSPO-immunofluorescence staining of cardiac and neural tissues
were also conducted. Our results indicated that DMD mice showed significant elevations in heart
and brain [18F]FEPPA activity, which correlated with increased ex-vivo fluorescence intensity. In
summary, this study suggests cardiac and neuroinflammation presence in DMD and highlights
TSPO-PET’s utility as a tool for in-vivo assessment of inflammation in several organs
simultaneously within DMD.

Keywords
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Summary for Lay Audience
Duchenne muscular dystrophy is characterized by progressive skeletal and heart
weakness, and cognitive impairment. Current therapies have increased patient longevity,
revealing the emergence of heart and brain degenerative symptoms at the later stages of the
disease. Thus, there is a need to better assess, understand, and track the potential sources of
multi-organ dysfunction in DMD. Inflammation is thought to be a prime contributor to these
dysfunctions because it is widespread in both the DMD patient’s muscle and blood. However,
not much is known about inflammation in the brain of DMD subjects. This work addresses this
gap in knowledge through the assessment of inflammation in the brains and hearts of DMD mice
using live animal imaging and tissue measurements of [18F]FEPPA, a radiotracer that
accumulates in inflammatory cells. We found higher [18F]FEPPA in the hearts and brains of
DMD mice compared to healthy mice. This research demonstrates that imaging using
[18F]FEPPA can be a useful tool to assess inflammation in multiple organs in live mice models of
DMD.
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Chapter 1
1

Introduction

1.1

Clinical Symptoms of Duchenne Muscular Dystrophy

1.1.1 Overview
Duchenne muscular dystrophy (DMD) is a fatal progressive neuromuscular disorder that
affects approximately 1 in 3600 males worldwide, becoming the most commonly
inherited pediatric muscle dystrophy. DMD is typically caused by a X-linked recessive
mutation in the DMD gene, resulting in a higher emergence of pathological symptoms in
males than females [1]. However, DMD can also occur as a result of new spontaneous de
novo mutations, which are thought to occur in approximately one-third of affected boys,
while the remaining cases are attributed to the mutation inheritance from their carrier
mothers [2,3]. Dystrophin proteins are present in several tissue types, but most notably
are found within skeletal muscle, cardiac muscle, neurons within the central nervous
system (CNS). In most cases, DMD is characterized by muscle weakness and
degeneration, alongside cognitive impairment. These symptoms are often exacerbated by
chronic inflammation, and ischemia, often followed by fibrosis until the patient succumbs
to an early death from cardiac or respiratory complications [4–6]. Although there is still
no cure, recent advancements in experimental therapies have prolonged both ambulation
and life expectancy to approximately ages 30-40 [6,7].

1.1.2 Life phases
Infant DMD boys are asymptomatic as the first noticeable symptoms often manifest at 25 years, resulting in a late average age of definitive diagnosis at 5 years old. At this time,
affected boys typically present lower limb and trunk muscle weakness before substantial
muscular deterioration—causing gait problems, calf hypertrophy, Gower’s sign, and
other orthopedic complications between the ages of 6-8. By the onset of puberty, the
majority of these affected patients will lose a substantial amount of motor function and
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become wheelchair-bound—by the age of 10-12—before cardiac and respiratory function
begin to deteriorate. The loss of respiratory muscular structures results in decreased
pulmonary function, increasing the likelihood of developing respiratory infection and
failure by age 20 [1,8,9]. Currently, developments in skeletal muscle treatments (e.g.
corticosteroids, gene therapies, etc.) and respiratory care (e.g. use of respiratory assist
devices, non-invasive ventilation, etc.) have had success in prolonging ambulation and
life expectancy of patients—increasing the average age of mortality from 15-19 to 30-35
[10,11]. However, with these increases in longevity, cardiac dysfunction has become the
major cause of morbidity in DMD patients [12].

1.1.3 Clinical Symptoms of the Dystrophic Heart
Cardiovascular complications in DMD— typically dilated cardiomyopathy and cardiac
arrhythmia—become detectable when the child reaches 10-12 years of age. A common
misconception is that the dystrophic heart is clinically silent until the patient reaches
puberty. However, pre-clinical signs of cardiomyopathy within patients—as young as 6
years of age—are abundant including sinus tachycardia and associated electrocardiograph
abnormalities, right ventricle hypertrophy, and wall motion abnormalities in
electrocardiograms. Around the age of 9-10, the first detectable signs of clinical
cardiomyopathy emerge as myocardial fibrosis and left ventricle enlargement, which is
then followed by ventricular dilation and dysfunction. From 10 years of age onwards,
there is a rapid progression of both cardiac dysfunction severity and prevalence [6,13].
The number of cardiomyopathy symptomatic DMD patients increases from 26% at 10-14
years of age to 72% at 18 years of age. At end-stages, virtually all DMD patients will
exhibit signs of cardiac abnormalities (i.e. conduction defects, arrhythmia, dilated or
hypertrophic cardiomyopathy) until they eventually succumb to heart failure [13]. It
should be noted that “typical” heart failure symptoms (e.g. orthopnea, dyspnoea, or
exercise limitations) are often absent or hidden by skeletal muscle impairment in DMD,
causing significant delays in evaluation and treatment [6,14].
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1.1.4 Clinical Symptoms of the Dystrophic Brain
As DMD is a neuromuscular disorder, there are cognitive and neuropsychiatric
implications associated with this disease. However, most literature prioritizes
investigating the skeletal muscle degeneration associated with DMD, resulting in
minimal knowledge on both cognitive and anatomical symptoms of the DMD brain.
Additionally, the literature regarding the DMD brain is still heavily debated on and is
often contradictory in nature. However, it is generally agreed upon that approximately
20-50% of DMD patients will exhibit cognitive and behavioural issues [15]. DMD boys
are reported to have an increased likelihood of intellectual disabilities relative to both the
general population and to their unaffected siblings—ruling out confounding
socioeconomic factors (e.g. familial income, parent education level, etc.) [16].
Quantitatively, DMD patients typically have an average intelligence quotient (IQ) of
approximately 85, which is one standard deviation below the average population. These
reductions remain consistent when assessing Full Scale Intelligence Quotient tests
(FSIQ), although these patients seem to demonstrate lower verbal IQ scores (VIQ) but
not performance (PIQ). Both IQ and FSIQ scores in patients appear to be non-progressive
as neither were observed to correlate with age nor disease severity [17,18].
While IQ and FSIQ are a good measure of general intelligence, it should be noted that
DMD patients also suffer a specific pattern of cognitive and behavioural symptoms—
albeit with considerable variability between individuals. Broadly, DMD patients can
exhibit specific impairments in phonological awareness/processing, attention, visuospatial abilities, both verbal and visual working memory, and other executive functions
(i.e. planning inhibition, set shifting, etc.) [17–19]. Cognitive impairments may manifest
in school-aged DMD boys as limited vocabulary, poor language comprehension,
inattention, weak working memory, and learning disabilities in reading, mathematics, and
writing (i.e. dyslexia, dyscalculia, and dysgraphia) [20]. These deficits in cognitive
function seem to persist during adulthood, as adult DMD patients (mean age of 30) seem
to experience impaired attention, poor memory, and an inability to process auditory
information [21]. DMD also shares brain-related comorbidities with the development of
several other neurological and psychiatric disorders, such as an increased prevalence of
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epilepsy (7.9%), autism spectrum disorders (15%), anxiety disorders, attention-deficit
(hyperactivity) disorder (32%), and obsessive-compulsive disorders (4.8%). Interestingly,
this is also found with transient neurological attacks [22]. For instance, in a retrospective
review study of 59 males; patient records indicated that arterial ischemic stroke was more
prevalent in DMD patients (occurring at an incidence of 1 per 100 patient years in
comparison to current childhood ischemic stroke incidence of 1.6 per 100,000) [23,24].
At the same time, literature also indicates a high degree of inter-individual variability
across cognitive symptoms between DMD patients. These symptoms cover a broad range
of cognitive abilities—in which some are highly expressed, while others are nonexistent
in particular individuals [17–19].
Similar aspects of heterogeneity are also prevalent within the anatomical architecture of
DMD brains. For instance, some studies have indicated morphological abnormalities,
while others suggest no gross structural differences between the dystrophic and healthy
patient. In general, the dystrophin-deficient brains reportedly experience neuronal
loss/reduced brain weight, gliosis, cerebral heterotopia, increased cortical thickness, and
various alterations to brain microstructures (i.e. aberrant dendritic development and
arborization, altered synaptic ultrastructure, etc.) [17,25–27]. However, these features are
inconsistent and seem to vary between individuals. For instance, upon evaluating the
post-mortem attributes of 13 DMD patient brains, the majority displayed no difference in
brain weight nor gross anatomical structures. Despite no major anatomical differences,
three patients within the study demonstrated histological dendritic abnormalities and
arborization, while another patient demonstrated severe neuronal loss, astrogliosis,
purkinje cell loss, and cerebral heterotopia [28]. While it is still uncertain if these
morphological abnormalities are associated with impaired cognitive function, some
neuroimaging studies have demonstrated decreased glucose metabolism within select
regions of the dystrophic brain—which is typically indicative of cognitive impairment
[17]. Interestingly, some studies have also indicated possible cerebral degeneration within
DMD patients. For instance, using computer tomography (CT), Yoshioka et al. [29]
observed that older DMD patients displayed more severe cerebral atrophy (i.e. enlarged
internal and external cerebrospinal fluid space, abnormal cistern and sulci evaluation)
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than the younger patients. Despite these investigations, no correlation was found between
IQ, age, and DMD disease severity within these patients.
Historically cognitive symptoms appear to be non-progressive in DMD patients.
However, recent studies have indicated that these cognitive deficits may progress, but its
phenotype is only seen within older subsets of both DMD patients and animal models
[21,30,31]. For instance, within a comparative executive function study using the
Wisconsin Card Sorting Test (WCST), DMD patients (aged 30-37) had an average
WCST score that was nearly 50% lower than their younger DMD counterparts (age 1825) [30]. These results were consistent within aged mdx mice (age 18 months), as they
displayed decreased hippocampal spatial learning, impaired memory, and heightened
anxiety-related behaviour compared to their younger counterparts (age 4 months) [31].
This indicates that with increasing age, DMD patients may experience delayed-onset
neurodegeneration, possibly further hindering the quality of the later stages of their lives.
Thus, due to the improved management of skeletal and respiratory dysfunctions, more
patients are now surviving long enough for the emergence of heart failure and cognitive
impairment associated with the later stages of the disease. With this increased longevity
in DMD patients, the clinical relevance of downstream cardiac and neurodegeneration
become abundant, increasing the need for a better understanding of both cardiac and
neurological involvement. As such, this thesis will primarily focus on the dystrophic
heart and brain.

1.2

Pathophysiology

1.2.1 Overview of Dystrophin
The DMD gene, notably the largest gene in the human body, contains nearly 2.5 million
DNA base pairs and 80 exons. Being tightly regulated by sets of internal promoters, it
produces a diverse plethora of protein isoforms (called dystrophin protein variants) with
unique functions specific to various tissues of the body (e.g. retina, skeletal and cardiac
muscle, brain, schwann cells, etc). Examples of these dystrophin protein variants include
full length dystrophin Dp427 (mainly expressed in skeletal and cardiac muscle), and
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Dp140 and Dp71 (mainly expressed in the brain) [12,25,32]. Duchenne muscular
dystrophy arises due to a mutation in any region within the DMD gene, with the most
common being a frameshift mutation due to a deletion of one or more exons. The lack of
functional dystrophin, within several regions of the body, can lead to various symptoms
as this disorder simultaneously affects multiple organs—further building on DMD’s
reputation as a systemic disease [12,33].

1.2.2 Dystrophic Cardiac Pathology
Dp427 is the resident dystrophin isoform within the skeletal and cardiac muscle,
specifically located on the inner side of the sarcolemma within myocytes. It is
hypothesized that dystrophin forms the dystrophin-associated protein complex (DAPC)
along with other transmembrane proteins (i.e. dystroglycans, sarcoglycans, etc.), and
serves as a link between the cytoskeletal actin filaments, contractile units of myofibers,
and the extracellular matrix’ laminin protein (Figure 1.1). As such, dystrophin
mechanically stabilizes the plasma membrane during contraction by transferring the
forces generated by the sarcolemma to the extracellular matrix. In addition, dystrophin
(and the DAPC) is also integral in enabling signal transduction between the intra- and
extracellular environment. A notable example is neuronal nitric oxide synthase (nNOS),
which is localized to the sarcolemma by dystrophin. This facilitates the nitric oxide (NO)
synthesis signaling pathway and subsequently signals blood vessels dilation, allowing the
passage of oxygen and nutrients to muscle cells [34–36].
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Figure 1.1 Dystrophin serves as an integral component of the Dystrophin-associated
protein complex (DAPC) and links the actin cytoskeleton to extracellular matrix
(ECM). Schematic displays the binding of the actin cytoskeleton-bound dystrophin to
DAPC transmembrane proteins (i.e. sarcoglycan, dystroglycans), which anchors lamininbound ECM. This complex serves to stabilize the sarcolemma during muscle contraction.
Dystrophin may also interact with additional proteins (i.e. nNOS) at the sarcolemma,
allowing for signal transduction [35].
Within dystrophinopathies, there are many theories for the degeneration of cardiac
muscle. Among them is the “two-hit” hypothesis model, which speculates that the
dystrophic phenotype is not caused by one exclusive mechanism, but rather the
cumulative effects of multiple stressors. In this model, the first “hit” is the destabilization
of the DAPC. During DMD, the absence of dystrophin (and associated DAPC) causes the
muscle cells to be vulnerable to mechanical stress, increasing the susceptibility of the
cells to damage during cardiac muscle contractions. As a result, contractile forces cause
the shearing and tearing of the sarcolemma membrane [4,34,37]. Immune cells (i.e.
neutrophils, mast cells, and macrophages) are recruited to the sites of mechanical damage
to help with phagocytosis of cell debris and to release inflammatory cytokines that can
instigate myonecrosis [5,38]. Additionally, the myocyte’s tearing can increase membrane
permeability, causing an abnormal influx of calcium ions from the extracellular space
into the cell. Furthermore, this dysfunctional calcium influx may be a result of
impairments to the L-type calcium channels and mechanical stretch-activated receptors—
which regulates the depolarization and contraction of the cardiomyocyte via calcium ions.
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This intracellular calcium causes further problems as it can activate proteases (e.g.
calpain), which are thought to degrade a wide variety of contractile proteins and induce
myocyte necrosis [36,38,39].
The second “hit” is often described as damage that is environmentally or indirectly
induced [12]. For instance, the excess calcium levels within myocytes were also found to
trigger the release of reactive oxygen species (ROS). In cardiac muscle, ROS promotes
inflammatory cell recruitment by activating inflammatory signaling pathways (i.e. NFkB) and releasing pro-inflammatory cytokines [38,41–43]. These immune cells (e.g. M1like and M2-like macrophages, neutrophils, T-cells, etc.) are recruited and typically
found at the site of cardiac injury [44]. In particular, pro-inflammatory macrophages are
thought to attack cardiac myofibers and exacerbate the myonecrosis process upon chronic
activation, further damaging the sarcolemma [5,38,45]. Additionally, ROS can trap these
macrophages at the site of inflammation by upregulating cytokine macrophage migration
inhibitory factor—prolonging the damage [46]. During this myonecrosis process, these
inflammatory macrophages can also release pro-inflammatory cytokines, which may
trigger fibroblasts to produce collagen in the extracellular matrix. Increased collagen
deposition is notably dangerous, as it leads to fibrosis—particularly in regions of high
contractility and movement (e.g. left ventricle). As a result, elastic cardiac muscle is
replaced with segments of rigid fibrotic tissue, which can cause pre-clinical symptoms of
cardiomyopathy such as conduction defects or decreased systolic ejection [38,39,44].
Ischemic injury, caused by the mislocalization of neuronal nitric oxide synthase (nNOS),
can also contribute to acute myocyte death. nNOS is normally bound to the sarcolemma
by the DAPC. Thus, with dystrophin’s absence, nNOS is unanchored and will localize to
the cytosol. This process causes vasoconstriction of the blood vessel—leading to
inadequate blood flow, poor oxygen regulation, and ultimately muscle ischemia. The
rapid accumulation of inflammatory cells to the site of ischemic injury may also lead to
the induction of myonecrosis [47–49].
In summary, current literature dictates that the DMD cardiac phenotype is the product of
several complex and multi-faceted cascades arising from the dystrophin protein
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dysfunction. While mechanical injury and membrane defects are thought to be the initial
causes of DMD, secondary mechanisms encompassing chronic inflammation, fibrosis,
and ischemia also seem to contribute to this defective pathophysiology. Thus, a better
understanding

and

tracking

of

these

secondary

mechanisms—specifically

inflammation—may lead to a better understanding of cardiac outcomes.

1.2.3 Dystrophic Neural Pathology
Unlike the full-length dystrophin (Dp427) found in cardiac and skeletal muscle,
dystrophin within the brain are expressed as several protein isoforms of varying lengths.
Different isoforms (e.g. Dp427, Dp140, and Dp71) are localized to specific brain
regions/cells and participate in various cellular functions. For instance, Dp427 typically
localizes to the neurons in the cerebellum, cortex, and hippocampus, while Dp71
typically localizes to astrocytes and glial cells [25,32,50]. While the etiology behind
DMD patients’ cognitive symptoms remain unknown, it is suspected to be caused by a
mutation to certain regions of the DMD gene leading to the loss of one or more
dystrophin protein isoforms [25]. For instance, in a large genetic study containing 65
DMD patients, the risk of cognitive deficit—portrayed by FSIQ scores—is highly
correlated to gene location and the resultant types of isoforms lost. Here, patients who
had lost the shorter isoforms (i.e. Dp71) yielded the lowest FSIQ compared to those who
lost only the longer isoforms (i.e. full-length Dp427) [51]. As such, the heterogeneity of
DMD cognitive dysfunction is thought to be caused by the cumulative loss of different
dystrophin isoforms.
Unfortunately, the exact function of each dystrophin protein variant within the brain is
still vastly uncharacterized. Within murine models, Dp427 has been found to colocalize
with a subset of γ-aminobutyric acid (GABAA)—a neurotransmitter important for the
regulation of learning and memory— receptors clusters within the synaptic regions of the
cerebellum, cerebral cortex, and hippocampus [50,52,53]. Alike to muscle cells, Dp427 is
suspected to be integral to the formation of DAPC-like structures within the brain, which
may aid in the stabilization/anchoring of GABAA receptors to the neuronal post-synaptic
membranes [54]. In support of this, mdx mice were observed to have a notable reduction
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in the number of GABAA receptor clusters in the cerebellum [53]. As such, Dp427 may
play a role in maintaining GABAergic synaptic function. The loss of Dp427 may alter
signal transduction/synaptic plasticity, leading to learning/memory deficits seen in DMD
patients [54,55].
Despite being the most abundant dystrophin protein variant in the adult brain, Dp71
typically localizes to perivascular end-feet of astrocytes and clusters of water channel
protein aquaporin-4 (AQP4) receptors [32,56]. Both of these structures are important in
maintaining the blood-brain barrier (BBB). Astrocytes’ end-feet processes interact with
endothelial cells and pericytes form tight junctions to restrict the entry of non-specific
molecules from circulation into the brain. On the other hand, AQP4 channels control
water influx into the brain. Thus, it is suspected that Dp71 may contribute to the
modulation of BBB permeability [32,57,58]. While the exact role of dystrophin protein
within the BBB has yet to be confirmed, several investigators have demonstrated its
importance in maintaining BBB function/vascular permeability through several DMD
murine studies. For instance, Nico et al. [58] observed that the BBB of mdx adult mice—
a murine model of DMD—suffered severe damage and subsequently disrupted. Most
notably, the authors histologically observed increased vascular permeability, less
endothelial tight junction protein expression, decreased AQP4 protein, and the emergence
of swollen and degenerating perivascular end-feet, marked by a discontinuous
envelopment of endothelial vessels. Similar incidences of disrupted BBB integrity and
cerebral diffusivity were confirmed to occur in-vivo in mdx mice [59]. To the best of my
knowledge, the correlation between BBB disruption and cognitive impairment within
DMD has yet to be studied. However, it is common for BBB breakdown to initiate
cognitive impairment within several other neurodegenerative diseases (e.g. Alzheimer’s
dementia, Parkinson’s disease, and multiple sclerosis) [60]. Interestingly, an altered BBB
integrity coupled with increased neuroinflammatory infiltration is thought to contribute to
the increased risk of Autism spectrum disorder and epilepsy—both common
comorbidities in DMD patients [61,62]. As such, it is possible that the altered BBB
permeability seen in DMD mice is also associated with neuroinflammation, which in turn
can contribute to the emergence of DMD cognitive impairment and neurodegenerative
symptoms.
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Although chronic inflammation is a key component of DMD muscle pathophysiology,
only recently has there been increasing consideration of neuroinflammation’s
contribution to cognitive impairment within this disease [54,63]. In a recent study, mdx
mice who exhibited DMD-like cognitive symptoms (i.e. impaired memory, depressionand anxiety-like behaviour) also had elevations of pro-inflammatory cytokines (i.e. IL-1β
and TNFα) and increased MPO activity (an analog for inflammation and leukocyte
infiltration) in their brains [64]. In support of this, two speculative reviews propose that
these pro-inflammatory cytokines are likely to disrupt hippocampal function in
dystrophinopathies, which facilitates learning/memory processing. For example, the
upregulation of IL-1β is speculated to modify GABAergic synaptic transmission by
altering the expression of inhibitory hippocampal GABAA receptors—features that are
typically observed in mdx mice. Although the mechanisms underlying these
inflammation-induced memory deficits are not well-understood, it is proposed that such
alterations may result in the increased potentiation of GABAergic inhibitory currents,
which is associated with memory deficits [54,63]. Thus, although the current literature
outlining inflammation’s role in dystrophic neuropathy are few and speculative in nature,
these findings highlight the potential role of immune molecules in modulating neurologic
function within the dystrophic brain.

1.3

Inflammation

Contributes

to

DMD

Cardiac

and

Neurologic Outcomes
While dystrophin-absent mechanical injury and membrane defects are thought to be
proximate causes of DMD, secondary mechanisms (such as chronic inflammation,
fibrosis, and ischemia) also contribute to the defective pathophysiology [5]. As
previously discussed in 1.2.1, chronic inflammation is an imperative component in DMD
cardiac muscle pathogenesis—as sarcolemma damage causes the recruitment of activated
glial cells and the secretion of pro-inflammatory cytokines. Due to the multitude of
signaling pathways and its participants, the mechanism to how inflammation affects
DMD muscle pathophysiology is highly complex. While the mechanism underlying how
each individual participant (e.g. neutrophils, M1-like and M2-like macrophages,
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inflammatory cytokines, etc.) affects dystrophic muscle remains unclear, they all
cumulatively contribute to the development of cardiomyopathy and possibly the eventual
emergence of heart failure [5]. In particular, macrophages are thought to have a central
role in exacerbating dystrophic muscle damage—since an abundance of macrophages and
neutrophils were shown to localize to regions of cardiac necrosis/lesions in
immunohistochemical staining of dystrophic mice hearts [45]. In addition, mdx models
with a predisposition for inflammation demonstrated extensive M1-like macrophage
infiltration and more severe cardiorespiratory dysfunction (i.e. decreased fractional
shortening and ejection fraction) compared to normal mdx models [38]. After removing
the macrophages from the muscle prior to the onset of myocyte necrosis (3-4 weeks),
mdx mice will later have a 70-80% decrease in number of injured muscle fibers (~3
months of age) [65]. These findings further demonstrate the importance of inflammation
in dystrophic cardiac outcome, emphasizing the need to better assess its presence in
DMD models as its attenuation may aid in slowing down cardiac dysfunction.
Similarly, neuroinflammation—depicted as heightened pro-inflammatory cytokines—in
the dystrophic brain is increasingly considered to be a contributor of cognitive
impairment associated with this disorder [54,63]. While much about this hypothesis
remain unclear, activated microglia—which commonly acts as the source and target of
these inflammatory cytokines—are implicit in the development of several other
neuroinflammatory and degenerative diseases, such as: Alzheimer’s dementia (AD),
Parkinson’s disease, and frontotemporal dementia [66]. Interestingly, activated microglia
have also emerged as a prime component of late-onset AD, in which similar to DMD, the
clinical symptoms of cognitive degeneration do not emerge until the later stages of life
[67]. To the best of my knowledge, no study thus far has demonstrated the presence of
activated microglia within the dystrophic brain. However, with this information and a
better understanding of neuroinflammation in DMD, there is the potential to develop antiinflammatory neuroprotective therapies that may improve patient’s cognitive function at
the later stages of this disease.
Due to the potential consequences of unchecked inflammation on the heart and brain,
there is a need to better understand the role of inflammation in multi-organ
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degeneration—as it may lead to the subsequent development of effective therapeutic
strategies that targets multiple bodily systems, especially brain and heart resilience in
DMD patients. However, a valid assessment tool must be developed in order to track
inflammatory status within several organs—especially in the heart and brain of DMD
patients.

1.4 Assessments of Inflammation
As previously discussed in section 1.3, inflammation holds a great deal of importance as
not only a localized response to tissue/organ injury, but also as a potential contributor to
downstream cardiac and neurological outcomes. As such, the assessment of inflammatory
response within DMD could aid in tracking disease progression and in developing
effective therapeutic strategies targeted to before the onset of severe cardiac or
neurological damage. Currently inflammation is not routinely monitored during clinical
DMD progression assessments. However, in other diseases, inflammatory load can be
assessed ex-vivo using in-fluid circulating inflammatory markers (i.e. C-reactive protein,
IL-6, etc.) and histopathological trafficking of immune cells, or in-vivo via non-invasive
molecular imaging [68]. Similar applications can foreseeably be done in DMD.

1.4.1 Ex-vivo Assessments
It is well-established in literature that inflammation can be assessed through several
different methods, ranging from: the novel inflammation-on-a-chip devices (an ex-vivo
contraption that uses microfluidic tools to visualize cellular events in a controlled tissue
microenvironment) to the more traditional and clinically-used biomarkers such as:
inflammatory cytokines (e.g. IL-6, TNF-α, IL-1β) and acute phase proteins (e.g. Creactive protein) [68,69]. Cytokines are secreted by immune cells (i.e. activated
macrophages and monocytes) at the site of inflammatory injury. However, they are also
found within circulation as they are crucial mediators of both local and systemic
reactions, allowing them to be contributors to the aetiology of chronic diseases [70].
Similarly, C-reactive protein (CRP) exhibit elevated expression during inflammatory
conditions in cardiovascular and cerebrovascular diseases [71,72]. These molecules can
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be significantly upregulated in response to tissue-induced inflammatory activity within 24
to 48 hours after initial insult [73]. These circulating inflammatory markers can be
measured ex-vivo by analyzing plasma/serum from blood or from other invasive locations
(e.g. saliva, urine, and cerebrospinal fluid). The use of in-fluid biomarkers is
advantageous because they are simple, fast to conduct, and are able to evaluate an
inflammatory or infectious state [74]. However, inter-individual genetic variations can
specifically increase plasma CRP levels regardless of inflammatory status, limiting its
sensitivity and specificity [73,74]. In addition, it does not identify the source nor target of
the inflammatory response, leaving little information on which organ(s) are damaged. As
such, despite in-fluid biomarkers’ ability to assess inflammatory status, it is limited in its
identification of the inflammatory location.
On the other hand, tissue-specific inflammatory information in the heart and brain can be
acquired ex-vivo with endomyocardial and brain biopsies. The removed segments of
neural and cardiac tissue are often histologically stained and microscopically examined,
allowing us to visualize and assess the extent and exact location of the inflammatory
infiltrate with a high degree of specificity [75,76]. However due to its invasive nature, the
amount of tissue obtained is minimal and thus, may not be representative of the whole
organ’s pathological status [77]. In addition, the localized nature of invasive tissue
biopsies is a concern within DMD assessment since DMD is a whole-body systemic
disease. This limitation can be extended to most ex-vivo vectors. As such, tissue biopsies
may be insufficient in observing inflammatory load within multiple organs
simultaneously without extensive surgical procedure, and the information obtained may
not even be indicative of that organ’s pathological state.

1.4.2 In-vivo Assessments
In-vivo imaging technology is understandably better suited than ex-vivo technology in
observing the overall inflammatory effects on a living subject in real time. In regard to
inflammatory imaging, there are a few alternatives that can be considered. For instance,
magnetic resonance imaging (MRI) has been used to evaluate the pathogenesis of several
inflammatory disorders and to study cardiac involvement in DMD patients [78,79]. This
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imaging modality uses an external magnetic field to first align the typically randomlyoriented hydrogen within water molecules in the subject. Various external radiofrequency
(RF) energies—also known as RF pulse sequences—are applied, resulting in the
excitation of the aligned proton atoms. Upon their relaxation from this excited state, the
proton will emit signals that are detected and recorded both temporally and spatially by
the scanner. These signals are then transformed, resulting in a high-quality anatomically
and structurally accurate image. Depending on the RF pulse sequence applied and the
detected relaxation time of the excited proton (known as T1- and T2- relaxation times),
different functional information can be inferred. Conventionally T2 relaxation times are
increased in tissue lesions or regions of edema (often associated with elevated
inflammation)—resulting in these regions appearing brighter than surrounding normal
tissue in MR images [79]. As a result, T2-relaxation time mapping is used to determine
the pathologic state of the affected tissue, while allowing us to identify the organ of
damage/region of inflammatory infiltration within the affected subject. In contrast to exvivo assessment tools, MRI can not only identify abnormal pathophysiology in tissuespecific regions, but can also image the entire body—allowing us to acquire information
regarding multiple organs simultaneously in one scan. While T2-weighted imaging has
been successful in differentiating between the muscle of DMD and healthy patients, its
specificity as a marker of inflammation is limited due to the confounding influence of
edema or fat infiltration [80,81]. In addition, inflammatory foci are virtually undetectable
in the earlier stages of disease progression if no blatant anatomical changes are present.
In summary, T2-weighted MRI may be a useful tool for the body-wide assessment of
DMD, but it is limited by its specificity and sensitivity in detecting inflammation.
Another imaging modality is positron emission tomography (PET). PET is a non-invasive
imaging technique that relies on the in-vivo detection of a radioactive tracer—also known
as a radiotracer—as it binds specifically to a region/receptor of interest. A radiotracer, by
definition, is the radioactive element-labelled (e.g.
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C, or
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O) ligand or substrate

that are highly specific for that targeted enzyme or receptor within the body. It is due to
this ligand-binding specificity that gives PET its identity as a molecular imaging
modality, as it can visualize and measure these biological processes at molecular and
cellular levels [82]. As such, PET offers higher sensitivity as it can detect imaging agents
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at a 10-11-10-12 molar level in contrast to MRI (at approximately 10-3-10-5 molar) and CT
(at approximately 10-2-10-3 molar) [83]. To conduct PET imaging, a tracer is administered
(usually by injection or inhalation). Depending on the positron-emitting radioisotope
bound to the tracer, a specific percentage of the nuclei will decay by emitting positrons.
These positrons generally travel a certain distance before colliding or annihilating with an
electron, resulting in the production of two 511keV photons that are expelled at a 180°
angle. Using opposing detectors within the scanner, the detection of these expelled
photons in coincidence allows for the localisation of the source of this emission (i.e. the
tracer) and tracer activity concentration within the subject. Thus, alike to MRI, this
imaging modality allows us to identify regions of affected pathophysiology
simultaneously in multiple organs in real time from a single scan. However, unlike MRI,
PET can identify the presence of inflammation at a much higher specificity depending on
the radiotracer of choice. To the best of my knowledge, there has yet to be a study
conducted with the goal of imaging inflammation in DMD using PET. However, this
imaging modality may be useful in assessing inflammatory status in-vivo as it has already
successfully demonstrated its utility in several other inflammatory disorders (e.g. cardiac
sarcoidosis, vasculitis, and rheumatoid arthritis) [84].

1.5

Inflammatory PET Radiotracers

1.5.1 Glucose-metabolism Analogue Tracer – FDG
The most extensively used radiotracer within both the research and clinical environment
is 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG), a glucose analogue that allows for the
quantification of glucose metabolism within metabolically active cells/tissues. While not
a direct marker of inflammation, it has shown significant value for successful imaging of
cardiac and neural inflammatory diseases, such as atherosclerosis, vasculitis, Alzheimer’s
dementia, and multiple sclerosis [85,86]. This can be attributed to the fact that immune
cells—in particular macrophages/microglia and neutrophils—have an increased demand
for glucose than peripheral non-inflammatory cells. As such, sites of significant
[18F]FDG uptake can be used to identify regions of activated macrophage accumulation
[83,87]. However, the imaging of inflammation with [18F]FDG PET has the tendency to
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yield false-positive results (e.g. accumulating in metabolically active benign tumors or
brown adipose tissue) [88,89]. In addition, the heart and brain are naturally very
metabolically-active organs. As a result, there is a higher level of tracer accumulation
within those areas, making it difficult to detect inflammatory infiltrates in those areas
without it being obscured by background activity [83,88]. Thus, there has been increasing
reliance on more specific inflammatory radiotracers that target macrophage or microglia
directly.

1.5.2 Translocator Protein (TSPO) Tracer – FEPPA
One candidate that has been increasingly used to image inflammation are radiotracers that
bind to translocator protein (TSPO). Also known as peripheral benzodiazepine receptor
(PBR), TSPO is a 18kDa transmembrane protein located on the outer membrane of
mitochondria, and is constitutively expressed at low-to-moderate levels in several organs
(e.g. kidneys, adrenal glands, lungs, and the healthy myocardium and brain parenchyma)
[90]. Specifically, within the healthy brain, TSPO is also expressed at minimal amounts
on resting microglial cells [91]. However, during cases of neurological disease/injury and
inflammation, TSPO is considerably upregulated specifically on activated microglia and
reactive astrocytes [92,93]. In fact, several studies have indicated a colocalization of
TSPO overexpression and activated microglia in both acute injury and chronic
degenerative disorders—including multiple sclerosis, Parkinson’s and Alzheimer’s
dementia [92,94]. For instance, audioradiograms and confocal microscopy demonstrated
that sites of TSPO-tracer binding overlapped with regions rich in CD68-stained activated
macrophages and microglia nodules in brain sections of macaques suffering from simian
immunodeficiency virus encephalitis [95]. As such, TSPO-PET is highly used in research
for the detection of regions particularly abundant in microglia activation, which are
typically regions associated with neuronal damage.
Recently, TSPO-PET radiotracers have been increasingly used outside of the neural
environment to image inflammation in peripheral organ diseases. Despite its ubiquitous
expression in several tissues, several studies have demonstrated significantly higher
levels of TSPO expression in peripheral organs during disease-induced inflammation than
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that of healthy controls [91,96]. For instance, the myocardium of experimental
autoimmune myocarditis models demonstrated an approximate 3.7-fold higher level of
TSPO expression than that of healthy controls. These areas of increased TSPO expression
were also colocalized immunohistochemically with regions highly concentrated with
CD68+ macrophages [97]. Likewise, autoradiography and immunohistostaining of a
murine CD68+ carotid, and fibrotic human carotid tissue samples indicated TSPO-tracer
localization within inflamed and damaged areas [98,99]. Furthermore, [11C]PK11195—
another TSPO radiotracer—has been successfully used to image both cardiac and
neuroinflammation within a patient post-myocardial infarction, demonstrating TSPOPET’s feasibility as a multi-organ inflammation-investigative tool [94]. Thus, the PET
imaging of TSPO in both activated macrophages and microglial cells, may be sensitive
enough for the in-vivo detection and quantification of inflammation body-wide within
DMD.
Currently there are several TSPO-associated radiotracers used in literature that have
successfully imaged both cardiac and neuroinflammation across several diseases [91,96].
Examples of these include: the historic [11C]-(R)-(2-chlorophenyl)-N-methyl-N-(1methylpropyl)-3-isoquinoline-carboxamide ([11C]PK11195), and the second generation
tracer

[18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide

([18F]FEPPA) [100,101]. [11C]PK1195 is the most widely studied and has vastly
contributed to delineating the role of inflammation in several acute and degenerative
disorders [102,103]. However, there is an increasing reliance on second generation TSPO
radiotracers (e.g. [18F]FEPPA) as they resolve some of the challenges associated with
[11C]PK1195—such as short half-life of
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C, better brain penetration, and increased

specificity [104,105] . Having been radiolabeled with 18F, these TSPO radiotracers have a
longer half-life of 109.8 minutes, allowing for more extensive research with relatively
less temporal restriction. In addition, [18F]FEPPA has comparatively better binding
potential, specificity, and penetrative ability of the BBB than [11C]PK1195—thereby
being a better in vivo assessment tool for inflammation in both the dystrophic heart and
brain [106].
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1.6

Pre-clinical Murine Models of DMD

There is an abundance of animal models for DMD, ranging from small non-mammalian
Drosophila melanogaster to larger newly developed pig models. However, rodent models
remain one of the most widely used vectors due to their genotypic and pathological
resemblance to DMD-diagnosed humans. Amongst the many strains is the mdx mouse,
which has no functional dystrophin protein due to a point mutation in the X-chromosome
of the DMD gene so that like its human counterpart, will possess no functional dystrophin
protein [107]. As a result, this murine model can demonstrate histopathological
characteristics of tissue degeneration and inflammatory infiltrate within skeletal muscle
[108]. In addition, mdx mice also exhibited signs of cognitive dysfunction in the form of
impaired visuospatial memory, impaired avoidance memory, anxiety, and depressive
behaviours within 8 weeks of age [64,109,110]. In addition, they are known to exhibit a
reduced capacity to learn and store spatial memories [109,111]. However, this strain’s
efficacy is greatly decreased as they exhibit none or mild non-progressive
cardiomyopathy even after 10 months of age—despite showing a degree of inflammation,
cellular necrosis, and fibrosis within their myocardium [112]. This can be attributed to
the compensatory effects of dystrophin protein homolog, utrophin. Unlike their human
counterparts, utrophin in mdx mice can substituted structurally for dystrophin within
muscle—restoring DAPC and subsequently leading to an improved muscle pathology
[113].
On the other hand, the mdx:utrn(+/-) mouse is able to exhibit a slightly more severe
phenotype as it only possesses one functional copy of the utrophin protein. For instance,
both skeletal and cardiac muscle of mdx:utrn(+/-) models exhibit more severe collagen
deposition and fibrosis than that of mdx mice [114]. As such, it is often referred to in
literature as a more accurate model of DMD phenotypically. To the best of my
knowledge, the cognitive impact within the mdx:utrn(+/-) model has yet to be
characterized. However, as these models depict a more severe phenotype, they are
predicted to show greater cognitive impairment than within the mdx model.
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1.7

Research Outline

Within this thesis, mdx:utrn(+/-) mice were utilized. Specifically, 8-10 week old murine
models were selected, as evidence of cognitive impairment and early signs of cardiac
fibrosis (but not cardiomyopathy symptoms) have been reported at this age [64,115]. This
age group may provide information about inflammation prior to severe tissue damage.
After an injection with [18F]FEPPA, PET images were taken of the whole body to better
assess inflammatory load collectively on a multi-organ level. In order to validate the
[18F]FEPPA PET data and quantify TSPO-tracer ex-vivo, autoradiography and
biodistribution were conducted on not only the heart and brain but also several peripheral
organs. Autoradiography was conducted on the thoracic and abdominal aorta, heart,
brain, gastrocnemius, soleus, extensor digitorum longus, tibialis anterior, and liver. In
addition to these tissues, biodistribution was also conducted on the large intestine, small
intestine, diaphragm, tibia/fibula, tail, pancreas, lungs, and spleen. These data provide a
better understanding of inflammation on a systemic level. Immunohistochemical staining
with anti-TSPO antibody was also examined to further validate if the TSPO-tracer is
localizing to the cardiac and neural tissue.

1.7.1 Study Objectives
1.

To develop a non-invasive imaging protocol to assess in vivo inflammatory
involvement in DMD simultaneously in several organs using [18F]FEPPA PET

2.

To investigate the role of inflammation in the heart and brain of DMD murine
models

1.7.2 Study Hypothesis
We hypothesized that subjects with DMD demonstrated heightened levels of
inflammation in dystrophic cardiac and neural tissues.
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Chapter 2
2

In-vivo imaging of cardiac and neuroinflammation in
Duchenne muscular dystrophy mice: a [18F]FEPPA PET
study

This chapter has been adapted from the following manuscript:
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy:
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under
Review. Manuscript ID: NWD-S-20-00539.

2.1

Introduction

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular degenerative
disease, affecting approximately 1 in 3600 live male births worldwide. Individuals with
DMD are unable to produce functional Dystrophin protein which is found systemically
across various tissues, notably in skeletal and cardiac muscle, and neurons in the central
nervous system (CNS). As a result, DMD is clinically characterized by progressive
skeletal and cardiac muscle degeneration along with cognitive impairment [1–3]. These
multi-organ degenerations are exacerbated by fibrosis, ischemia, and chronic
inflammation until an early death from cardiac or respiratory complications [4–6].
Although there is still no cure for DMD, recent advancements in experimental therapies
have prolonged both ambulation and life expectancy, as fatalities previously expected by
age 15–20, are now often observed at approximately age 30-40 [5,7].
Due to the improved management of skeletal and respiratory dysfunctions, more patients
are now surviving long enough for the emergence of heart failure and cognitive
impairment associated with the later stages of the disease. In fact, more than 90% of
DMD patients over the age of 18 show signs of cardiac involvement, with nearly 60% of
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DMD patients dying from cardiac complications by age 19 [8,9]. Likewise 20–50% of
males demonstrate some form of cognitive weakness which remain, and in some cases,
exacerbates as they get older (~age 30) [10–12]. Thus, with increased longevity in DMD
patients, the clinical relevance of heart disease and cognitive impairment in DMD is
becoming more apparent, increasing the need for the better understanding of both
dystrophic cardiac and neurological involvement. Currently, it is known that the
dystrophin loss in cardiac muscles leads to membrane integrity deterioration of striated
cardiac muscle fibers and impaired regulation of intracellular calcium levels. As with
skeletal muscle, it is suspected that this membrane instability and associated intracellular
calcium influx initiate the pathological cycle of chronic inflammation, fibrosis, necrosis,
leading to damage in regions of high contractility and movement (e.g. left ventricle). The
loss of viable myocardium leads to further fibrosis, and the clinical emergence of
cardiomyopathy and eventually heart failure [5,6,13–15].
The brain is a far less studied organ in DMD, but dystrophin also plays a role in brain
development and aging. The lack of intrinsic dystrophin gene products within CNS—
namely Dp427, Dp140, and Dp71—are thought to contribute to cognitive weakness by
contributing to a series of functional and morphological abnormalities within the
dystrophic brain [2,3,16]. However, the underlying mechanisms are not well understood.
Cognitive and behavioural symptoms usually manifest in the form of lowered intelligence
quotient (IQ) scores, learning difficulties, memory deficits, and higher incidences of
neuropsychiatric disorders [16]. Recent investigations also report the delayed emergence
of cerebral infarcts and progressive cognitive decline within older DMD subjects, leading
to the possible paradigm of neurodegeneration in the later stages of disease progression
[10,12,17].
While mechanical injury and membrane defects are thought to be proximate causes of
DMD, secondary mechanisms encompassing chronic inflammation, fibrosis, and
ischemia also contribute to the defective physiology. Indeed, inflammatory cell
infiltration is strongly associated with DMD as it is thought to exacerbate symptoms and
promote muscular degeneration [4,6,14]. We recently demonstrated that the degree of
inflammatory cell infiltration is correlated with disease progression within DMD murine
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models [18]. While there is growing evidence that inflammation may be an inciting factor
in skeletal muscle degeneration and the development of cardiomyopathy in DMD, the
role of inflammation within the dystrophic brain in DMD is relatively unexplored—
despite neuroinflammation being a prime proponent to several pediatric and adult
neurodegenerative disorders [4,19–21]. To the best of our knowledge, immune cell
infiltration has yet to be demonstrated within neither the DMD patient nor animal model
brain. However, in brain tissue from the mdx murine model of DMD, heightened levels of
pro-inflammatory cytokines in interleukin (IL)-1β and Tumor Necrosis Factor (TNF)-α
were found and several cognitive deficits were observed [22]. Other neurological diseases
are also associated with increased levels of TNF-α and IL-1β [23]. Thus, considering the
well-known consequences of unchecked inflammation potentially leading to cardiac and
neurodegeneration, there is an unmet need to better understand the role of inflammation
in multi-organ degeneration, as it may lead to the subsequent development of effective
therapeutic strategies that targets multiple tissues systems especially brain and heart
resilience in DMD patients.
Recent advancements in non-invasive molecular imaging techniques for assessing
inflammatory load have already inspired interest in understanding the role of
inflammation in multi-organ degeneration in several disease systems. In particular,
Thackeray et al. [24] demonstrated evidence of concomitant inflammation in both the
hearts and brains of ischemic heart disease mice and patients using positron emission
tomography (PET) imaging targeting mitochondrial translocator protein (TSPO). TSPOs
are highly expressed on activated microglia and macrophages [25]. Thus, this exploratory
study sought to explore the capacity of TSPO-PET imaging in assessing in-vivo
inflammatory involvement in DMD in the heart and brain as well as across several
organs. Specifically, we used [18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin3-yl)acetamide ([18F]FEPPA), a second-generation TSPO tracer, to assess cardiac and
neural inflammation in DMD [25]. We hypothesized that mice with DMD will have
increased inflammation levels in dystrophic cardiac and neural tissues, exhibited as
heightened TSPO-PET signal and correlative histological TSPO expression.
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2.2

Materials and Methods

The study was conducted at Lawson Health Research Institute at St. Joseph’s Health Care
in London, Ontario. All animal protocols were approved by the Animal Use
Subcommittee at Western University and were conducted in accordance with guidelines
set by the Canadian Council on Animal Care (CCAC).

2.2.1 Study Population
Breeding

pairs

of

wild-type

(C57BL/10)

and

functional

dystrophin-deficient

mdx:utrn(+/-) (a point mutation in dystrophin gene) mice were purchased from Charles
River and Jackson Laboratories (Bar Harbor, ME) [26]. Colonies were maintained under
controlled conditions (19-23˚C, 12-hour light/dark cycles), and were allowed water and
food ad libitum. Two separate groups of eight to ten week old mice were used in this
study where the in-vivo imaging (n=4-6 mice/genotype) and ex-vivo histology cohorts
(n=3

mice/genotype)

are

henceforth

to

be

referred

to

as

the

PET

and

immunohistochemistry (IHC) cohort, respectively.

2.2.2 Small animal PET Imaging Protocol
All PET mice were induced in a chamber with 3% oxygen-balanced isoflurane mixture
and then anesthetized with 1.5 – 2%; both mixtures were delivered at a constant rate of
1L/min via a nose cone. After induction, these mice were imaged using a micro-PET
scanner (eXplore VISTA, GE Healthcare; Inveon DPET, Siemens). To assess wholebody inflammation accumulation, TSPO-targeted PET images were obtained after
[18F]FEPPA tracer injection. 30 seconds following the start of the scan, a dose of
approximately 20 MBq of prepared [18F]FEPPA in saline (approximately 5μg/kg) was
administered via tail vein catheter for dynamic acquisition. Summarily, a 60-minute
whole-body dynamic scan in list-mode was acquired using the Inveon system. Upon
using the eXplore VISTA scanner, list-mode acquisition was also conducted upon a 60
minute dynamic scan of the head-to-chest region, followed by a 30 minute full-body
static scan. Injected dose did not exceed 0.3 mL to ensure proper animal health
conditions.
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2.2.3 PET Imaging Analysis
For each subject, the dynamic PET list mode data were reconstructed into the following
time frames: 12 × 10 s, 6 × 30 s, 5 × 60 s, 5 × 120 s, 8 × 300 s using ordered subset
expectation maximization (OSEM) algorithm with no scatter and attenuation correction.
Data were corrected to injected dose and decay corrected to start of PET scan using inhouse MATLAB v2019a scripts (Mathworks, Natick, MA, USA). Standardized Uptake
Values (SUV) were generated from PET data 30-60 minutes post-injection in PMOD 3.9
(PMOD Technologies, Zurich, Switzerland). Using manually drawn regions of interest
(ROI), mean SUV were calculated for the left ventricle, lung, and whole brain covering
3-4 slices. Left ventricle-to-heart ratio—used to offset lung [18F]FEPPA activity and act
as a correlative of cardiac events—was calculated from mean SUV within each animal
[27].

2.2.4 Biodistribution and Autoradiography
The mice were sacrificed immediately after imaging through 5% oxygen-balanced
isoflurane gas euthanasia followed by cervical dislocation. To preserve tissue anatomy,
the mice underwent whole animal perfusion fixation via an intracardiac infusion of 4%
paraformaldehyde (Sigma-Aldrich), and then phosphate-buffered saline (PBS) as directed
in Gage et al. [28]. The heart and brain were dissected from the subjects. Each heart was
bisected twice—once transversely and once along the septum—and each brain were
bisected along the central sulcus to ensure that exactly half of each tissue was fixed in
10% Formalin or frozen in Optimal Cutting Temperature solution (VWR) for
biodistribution and autoradiography use respectively. Biodistribution was conducted for
the heart, brain, thoracic aorta, diaphragm, gastrocnemius, soleus, tibialis anterior,
large/small intestines, tibia/fibula, kidney, liver, and lungs; each organ was weighed for
quantitative estimation of gamma counts from the

18

F conjugate using the ORETC

DSPEC50 Spectrometer. Radioactivity obtained from different organs was calculated as
the percentage of the injected dose per gram of the tissue (%ID/g) and decay corrected to
time of injection. Radioactivity was standardized to the dose injected into each animal.
For autoradiography, frozen tissue samples were cryosectioned into a thickness of 20 μm
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with a Leica Clinical Cryostat (CM1850, Leica Biosystems, Wetzlar, Germany).
Autoradiographic images of the heart, brain, thoracic aorta, diaphragm, gastrocnemius,
tibialis anterior, kidney and liver were acquired for 12 h using a digital autoradiography
system (JTV-18-0008, AI4R, Nantes, France) fitted with a HEEL positron holder.

2.2.5 Histology
2.2.5.1 Tissue Preparation
To supplement data from acute imaging for immunohistochemistry analysis, a cohort of
mice were sacrificed through cervical dislocation following CO2 gas euthanasia without
PET imaging. The heart and brain were dissected and fixed in 10% formalin for 24–48 h.
These tissues were processed for immunohistochemistry by being embedded in paraffin
by the Molecular Pathology facility (Robarts Research Institute, London, ON) and cut
into 10 μm thick sections. Care was taken to ensure that the tissues were embedded in the
same orientation within each block.

2.2.5.2 Immunohistochemistry Protocol
Following a modified protocol based on Abcam standards, tissue sections were
deparaffinized and rehydrated in a series of xylene and ethanol washes prior to heatmediated antigen retrieval in a citrate buffer for 30 minutes. Slides were then cooled
slowly to room temperature, and Background Sniper (Biocare Medical) was applied for 8
minutes to reduce nonspecific background staining. Sections were incubated overnight at
4 ℃ with either primary anti-PBR (1:200, Abcam), primary anti-α-SMA (1:500, Abcam),
or no antibodies—the latter acting as the positive and negative control. All antibodies
were diluted in 1% bovine serum albumin (BSA) PBS. Following thorough washing with
1 × PBS, Alexafluor IgG (Life Technologies, 1:500) secondary antibodies were used to
visualize the primary antibodies: anti-PBR sections were incubated with 594 Goat antirabbit IgG, and anti-α-SMA sections with 488 Goat anti-mouse IgG for 2 h at room
temperature. For heart tissue, a solution of Cu2SO4•5H2O was applied thereafter to
prevent red blood cell autofluorescence. Additional 1 × PBS washes and an immersion in
0.1% Sudan Black B was performed to quench autofluorescence in both heart and brain
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tissue sections. Lastly, ProLong Gold anti-fade with DAPI (Life Technologies) was
added to all sections to visualize the nuclei and to mount the coverslips onto glass slides.

2.2.5.3 Microscopy and Image Analysis
Fluorescent images were acquired on an epifluorescence microscope (Nikon Eclipse
Ts2R) using NIS Elements Microscope Image Software. Non-overlapping fields of view
at 60x magnification were taken for each tissue section (n=5-10 images/slide).
Quantitative assessment of TSPO fluorescent signal in both wild-type and mdx:utrn(+/-)
(henceforth named DMD) subjects—while minimizing image exposure and autofluorescence (i.e. background signal)—was performed using an in-house semi-automatic
grey scale thresholding protocol in ImageJ (LOCI, Wisconsin, USA) with FIJI package
v2.0.0 [29].

2.2.6 Statistical Analysis
Analyses were performed using RStudio v1.0.136 (Boston, MA, USA) or SPSS 26 (IBM,
Armonk, NY, USA) software. Data results are expressed as mean ± standard error (SE).
Comparisons between groups were performed using Welch’s two-tailed t-test. No
statistical analyses were conducted on autoradiography and biodistribution data due to
low sample sizes. Negative biodistribution values were removed from the data set.
Pearson correlation coefficients were calculated between [18F]FEPPA left ventricle/whole
brain uptake, and myocardium/neural tissue histological TSPO fluorescence intensity. Pvalues of less than 0.05 were considered significant. Replicate numbers are indicated in
the figure legends.

2.3

Results

A total of four DMD and six healthy mice were imaged. Both healthy and DMD mice
were both able to take up [18F]FEPPA throughout the entire body—notably binding to
our tissues of interest, the heart and brain (Fig. 2.1). Although there were not sufficient
tissue samples to measure differences in [18F]FEPPA binding using autoradiography and
biodistribution, preliminary results demonstrates [18F]FEPPA activity occurring body-

39

wide within the heart and brain as well as in several other tissues, such as skeletal
muscles, aorta, diaphragm, etc. as shown in Appendix Figure A.1 and Figure A.2.

Figure 2.1 [18F]FEPPA SUV images of representative 8-10 week wild-type (A, C, E)
and age-matched Duchenne muscular dystrophy (B, D, F) mice. Coronal whole-body
(A, B) and heart images (E, F), and axial whole brain slices (C, D) were generated from
PET time-activity curves at 30-60 minutes (n=4-6 mice/genotype). DMD=Duchenne
muscular dystrophy, SUV=Standardized uptake values.

2.3.1 Elevation of in-vivo inflammation-targeted radiotracer binding
in DMD models
To assess the influence of inflammation on dystrophic cardiac and neural tissue,
inflammation was quantified from the [18F]FEPPA PET images as mean SUV. In the
thoracic region, left ventricle-to-lung mean SUV ratios indicated that DMD mice had
significantly higher [18F]FEPPA uptake (Fig. 2.2; T1,7.62=2.58, P=0.0338), as these left
ventricle-to-lung ratios increased from 0.63±0.10 in healthy mice to 0.99±0.06 in their
DMD equivalents. In neural tissue, similar accumulations of inflammatory tracer were
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also observed in DMD mice. Healthy brains demonstrated [18F]FEPPA uptake of
0.34±0.08 SUV, while DMD brains experienced 45.4% more uptake at 0.62±0.08 SUV.

Figure 2.2 Quantified [18F]FEPPA activity in hearts (A) and brains (B) of agematched DMD and wild-type mice. Standardized uptake values were generated from
PET time-activity curves at 30-60 minutes using manually drawn regions of interest
(ROIs) segmented for the left ventricle, lung, and whole brain (n=3-4
slices/subject/genotype). Significant differences (p<0.05; indicated by *) were observed
between wild-type (white bars) and DMD mice (gray bars) for both left ventricle-to-lung
ratio (A) and whole brain (B) SUVs using Welch’s two-way t-test. Data are depicted as
mean ± standard error. TSPO = (18kDa) Translocator protein, other abbreviations as
described in prior figures.

2.3.2 Ex-vivo TSPO signal indicates heightened cardiac and
neuroinflammation in DMD
Fluorescence immunostaining of heart and brain slices confirmed the presence of TSPO
in age-matched DMD subjects. Although both groups expressed a modest baseline level
of TSPO (Fig. 2.3); consistently, DMD mice expressed significantly higher TSPO
fluorescence intensity in both cardiac (Fig. 2.4; T1,31.2=2.35, P=0.025) and neural tissue
(Fig. 2.4; T1,69.2=5.15, P<0.001). Within cardiac tissue, DMD mice experienced a 63.9%
increase in fluorescence intensity when compared to age-matched wild-type mice; as
dystrophic hearts demonstrated TSPO fluorescence intensities of 1261.57±307.76 AU
compared to those of wild-type mice at 454.59±63.93 AU. Similarly, in neural tissue,
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TSPO fluorescence intensity was remarkedly 68.3% lower in healthy controls compared
to DMD mice. Dystrophic brain tissues displayed fluorescence intensities of
1149.74±148.35 AU, which is lower than the 364.84±73.71 AU observed in wild-type
brains. Histological myocardium TSPO signal significantly correlated with [18F]FEPPA
uptake in the left ventricle (Fig. 2.5; r=0.59, p=0.037). This was also observed between
neural tissue TSPO fluorescence intensity in histology and in-vivo whole brain TSPOPET tracer SUV values (Fig. 2.5; r=0.57, p=0.042).
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Figure 2.3 Ex-vivo histology of TSPO-bound microglial and macrophages in DMD
and healthy subjects’ cardiac (A) and neural tissues (B). Representative fluorescence
immunostained images of microglial and macrophages with TSPO (red) and DAPI (blue)
in 8-10 week old subjects depict qualitatively more prevalent TSPO expression in DMD
mice. White arrow heads indicate regions of TSPO signal. Scale bar= 20μm.
Abbreviations as described in prior figures.
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Figure 2.4 Quantified fluorescence immunohistochemical images of microglial and
macrophages with TSPO in 8-10 week old DMD and healthy subjects. Data
(mean±SE) depicts higher TSPO in DMD mice (gray bars) than wild-type controls (white
bars) (n=3 mice/genotype). Significant differences (p<0.05), indicated by *, were
observed for slices of cardiac (A) and neural (B) tissue when compared using Welch’s
two-way t-test (n=5-10 images/subject/genotype). AU= arbitrary units. Other
abbreviations as described in prior figures.

Figure 2.5 Correlation of [18F]FEPPA uptake with histological TSPO fluorescence
intensity. Data depicts the significant correlation of the left ventricle (A) or whole brain
(B) SUV, with quantified TSPO myocardium or neural tissue fluorescence signal.
Pearson product-moment correlation coefficients (r) were calculated on all PET animals
(n=10). Significance was considered when p<0.05. Abbreviations as described in prior
figures.
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2.4

Discussion

The goal of this exploratory study was to evaluate the ability of [18F]FEPPA PET as a
tool to assess inflammation in-vivo in multiple organs of mice with dystrophic disease.
We found dystrophin-deficient mice had elevated [18F]FEPPA uptake in cardiac and
neural tissues compared to healthy controls, which mirrored heightened ex-vivo TSPO
levels in our histological data. These results support our hypothesis that subjects with
DMD demonstrate significant inflammation in their heart and brains using TSPO-PET.
To the best of our knowledge, our study is one of the first to observe significantly
elevated TSPO-PET in the heart and brains of DMD mice. Interestingly, these increases
seem to be occurring body-wide within several other tissues, akin to other diseases linked
to chronic inflammation (e.g. atherosclerosis, myocardial infarctions, etc.) [24,30,31]. As
such, it is likely that this heightened TSPO activity may be a consequence of activated
macrophages and microglia within regions of tissue injury or dysfunction [31]. For
example, immunohistostaining of mice one week post-myocardial infarction indicated
colocalization of TSPO to CD68+ microglia and cardiac monocytes within the brain
cortex and infarcted myocardium respectively [24]. Interestingly, no colocalization was
found between TSPO and GFAP-stained astrocytes at that time point. TSPO-tracers were
also found to localize to magnetic resonance imaging (MRI)-identified ischemic lesions
within ischemic stroke patients, further demonstrating the tracer’s feasibility to also map
inflammation after incidences of tissue damage [32]. Thus, as DMD pathophysiology is
known to be associated with contraction-induced damage and severe immune cell
infiltration, it is likely that TSPO is upregulated within regions of injury—manifesting as
the displayed [18F]FEPPA tracer uptake within the dystrophic heart and brain. Our
preliminary biodistribution and autoradiography observations support these claims, as the
TSPO-tracer accumulated notably within regions associated with DMD symptoms (i.e.
heart, brain, skeletal muscles, etc.). Although this exploratory study demonstrated the
feasibility of [18F]FEPPA PET to assess in-vivo inflammation simultaneously within the
heart and the brain, our study cannot provide a definite answer to whether [18F]FEPPA
PET can demonstrate inflammatory load within other tissues—despite the promising
trends—due to the small sample sizes of our autoradiography and biodistribution data. To
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answer this question, a study using a larger sample size as well as the quantification of
tracer uptake in the other tissues within the PET data is needed.
In contrast to our results, three previous 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)
PET studies reported lower mean cardiac SUV and highlighted select neural regions of
hypometabolism in DMD canine hearts and patient brains, respectively [33–35]. While
[18F]FDG can be used as an analogue of inflammation in several neurological and cardiac
diseases, it should be noted that these specific studies were focused on investigating the
metabolic functionality of dystrophin-deficient tissue regions rather than its associated
peripheral inflammation [36,37]. Because of the heart and the brain’s disposition as
highly metabolically-active organs, there is naturally a higher accumulation of [18F]FDG
tracer within those regions, which makes it difficult to detect inflammatory infiltrates
within either organ without it potentially being obscured by background activity or
alterations in myocardial/neuronal function [38,39]. Additionally, a multi-tracer study
longitudinally tracking microglial activation and glucose hypometabolism simultaneously
in a transgenic mouse model of Alzheimer’s disease observed discrepancies between the
data trend of the TSPO-tracer [18F]GE-180 and [18F]FDG [40]. The authors observed
progressive increases in [18F]GE-180 uptake throughout the entire course of the disease
(5-16 months), which differed from the life-course kinetics of [18F]FDG which peaked at
~8 months of age before decreasing for the remaining 8 months, suggesting that the
incidences of hypometabolism demonstrated within the dementia subjects are occurring
much later in life and as disease progressed. Interestingly, this early hypermetabolism
may be capturing increased glial activity as it matches the peak of [18F]GE-180 at 8
months—indicating the potential early onset of inflammation prior to rampant
hypometabolism (and with it, the neurodegenerative symptoms) [41]. Taken together,
although prior [18F]FDG studies in DMD subjects show known indications of late-life
brain and cardiac degeneration/dysfunction, our data highlights the potential role of
inflammation in contributing to these metabolic deficiencies within DMD mice. Further
longitudinal multi-tracer studies on dystrophic subjects using both [18F]FEPPA and
[18F]FDG would greatly improve our understanding of the time course and interaction of
inflammation and glucose hypometabolism onset.
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The increased in-vivo [18F]FEPPA activity within the heart of our DMD mice correlated
with increases in ex-vivo histology, demonstrating that TSPO overexpression seems to be
localized to the dystrophic myocardium. We suspect that this overexpression indicates the
presence

of

inflammatory

cell

infiltration—presumably

primarily

activated

macrophages—to the hearts of 8-10-week old dystrophic mice. Although we
acknowledge that TSPO is known to be constitutively expressed within cardiac tissue, the
mRNA profile of TSPO typically remains at a steady moderate state within normal
healthy tissue [42,43]. Importantly, TSPO is found to be overexpressed in inflammatory
cardiac foci, seemingly being upregulated in activated immune cells [44,45]. TSPO-PET
has similarly been used as a marker of cardiac macrophage infiltration in previous studies
of myocarditis, and myocardial infarction [24,44]. As such, it is suggested that these
heightened [18F]FEPPA activities may indicate activated macrophage presence within the
murine dystrophic heart.
Macrophage recruitment to the DMD heart is not unique to this study, as the well-known
narrative of dystrophic cardiac degeneration is centered around inflammation-exacerbated
damage, following dystrophin-deficient cardiac muscle contraction. It is currently
hypothesized that similar to the skeletal muscle, these high incidences of inflammation in
DMD cardiac tissue may be the result of a longstanding contraction-induced damage
cycle caused by dystrophin loss [4,13,46]. The lack of dystrophin protein within
cardiomyocytes, shows increased susceptibility of the sarcolemma to damage from
muscle contractions, resulting in a “leaky” plasma membrane [13,47]. In addition,
dystrophin-deficient cardiomyocytes are found to have significantly impaired L-type
calcium channels and mechanical stretch-activated receptors, which normally promote
the influx of calcium ions from the extracellular matrix and contribute to depolarization.
Due to impaired calcium channels, excessive calcium overflow occurs within
cardiomyocytes, which increases reactive oxygen species and subsequently triggers the
NF-kB signaling pathway [13,48]. This prompts the further release of inflammatory
cytokines and the recruitment of macrophages, lymphocytes, and other cells [49]. This is
one possible contributor of cardiac inflammation. Additionally, the improper channel
functionality may result in the influx of excess calcium ions, activating proteases within
the cell and initiating an auto-digestion process of the remaining myocytes, thus
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beginning the cardiac degenerative process [13,47,48]. To help with phagocytosis, these
necrotic cardiomyocytes may trigger the recruitment of macrophages, which can release
pro-inflammatory cytokines. These cytokines may trigger fibroblasts in the extracellular
matrix to produce collagen, leading to fibrosis—particularly in regions of high
contractility and movement (e.g. left ventricle) [5,14,15]. As a result, elastic cardiac
muscle is replaced with rigid fibrotic tissue, subsequently leading to the iconic
cardiomyopathy associated with DMD.
Our data, highlighting the presence of TSPO-bound ligands in DMD subjects and the
histological evidence of M1-like (proinflammatory) and M2-like (reparative) macrophage
infiltration into the sites of DMD injury support this hypothesis [50–52]. Interestingly,
these suspected elevations in inflammatory load are observed quite early at 8-10 weeks—
when the mdx:utrn(+/-) model heart function is relatively stable. This agrees with earlier
reports that indicate a certain degree of inflammation, cellular necrosis, and fibrosis
within their myocardium at 10 weeks of age [53]. However, it should be noted that one
cardiac DMD murine study found a lack of macrophage infiltration into cardiac tissue
until 6 months of age—in contrast to our results [54]. This delayed inflammatory onset
might be due to the authors’ use of mdx mice, a comparatively less severe model than
ours, as it is known to demonstrate minimal—if any—cardiac dysfunction [55,56].
Within studies pertaining the same murine model as ours, evidence of ventricular
dysfunction (i.e. impaired stroke volume, decreased ejection fraction, and elevated heart
rate) were observed far later at 10 months of age, compared to our observed onset of
cardiac inflammation at 8-10 weeks [57]. Thus, the present findings may indicate an early
onset of cardiac inflammation prior to the onset of cardiac symptoms. Considering that
mdx:utrn(+/-) mice who were started on an anti-inflammatory quercetin-enriched diet at
8 weeks of age have comparatively minimal cardiac damage than those without, the early
detection and intervention to modulate cardiac inflammation may be vital in possibly
attenuating downstream DMD cardiac degenerative symptoms [58]. A more extensive
explanation of this mechanism is outside of the scope of this paper. However, a further
longitudinal study pairing this [18F]FEPPA PET protocol with an anatomical or
morphological modality (such as MRI), may be undertaken to better assess how this early
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inflammatory response may contribute to the pathology of dystrophic cardiac tissue
damage.
[18F]FEPPA was originally designed and is still commonly used to assess activated
microglia, as an analogue of neuroinflammation. In-vivo [18F]FEPPA SUV has been
correlated with post-mortem pro-inflammatory markers histologically in other
neuroinflammatory or disease models, validating its use as an analogue of activated
microglia cells [59]. In the current study, in-vivo [18F]FEPPA signal within the whole
brain was found to correlate with ex-vivo TSPO immunofluorescence intensity,
suggesting the possible localization of activated microglia to the dystrophic neural tissue.
To the best of our knowledge, there are no other study demonstrating the presence of
immune cell infiltration into the dystrophic brain. However in support of our
observations, heightened levels of pro-inflammatory cytokines interleukin (IL)-1β and
Tumor Necrosis Factor (TNF)-α (molecules commonly associated with neurological
immune response) have been found within the brains of mdx mice, who also displayed
cognitive impairment similar to those in DMD patients [22]. Recent literature has also
speculated that these specific cytokines may participate in the emergence of DMD
cognitive dysfunction symptoms by altering several features in synaptic transmission (see
review in Rae and O’Malley [60] and Stephenson et al. [61]). Considering that activated
microglia are known to upregulate TSPO expression and release pro-inflammatory
cytokines (e.g. IL-1β, IL-6, TNF-α), it is possible that the activated microglia may
contribute to the dystrophic brain’s impairment [24,62,63]. Additionally, the activated
microglia may also predict cognitive deterioration as multiple studies regarding
neurodegenerative diseases—such as Alzheimer’s dementia—have reported that the
degree of neuroinflammation can predict longitudinal cognitive decline [64]. Similarly, it
is widely accepted that the earliest manifestation of some neurodegenerative diseases is
microgliosis, which are evident before the onset of clinical symptoms [65,66]. While the
underlying mechanism on how activated microglia contributes to downstream
neurodegeneration is still under debate, the early observation of neuroinflammation
within our study and the knowledge of late-onset cognitive decline within both older
DMD patients (occurring at 30 years of age) and aged murine models (occurring at 18
months) suggests a possible similar association [10,12]. As such, a future study using
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TSPO-PET to longitudinally assess neuroinflammation in these DMD murine models—
alongside cognitive testing—is suggested to better delineate the relationship between
early neuroinflammation and late-onset cognitive decline.
A possible explanation for this microglia activation within the brain may, in part, be due
to pro-inflammatory cytokines—which are abundant in DMD circulation—passing
through the “leaky” dystrophin-deficient blood-brain barrier (BBB) [4]. Within the brain,
dystrophin—specifically Dp71—is located in the perivascular end-feet of astrocytes,
normally participating in the stabilization and regulation of molecules transporting
through the BBB [67]. In mdx mice, the reduction of Dp71 demonstrates severe alteration
of endothelial and glial cells, as well as a reduction in the expression of zonula occludens
and Aquaporin-4. As a result, mdx mice shows increased vascular permeability and by
proxy, increased permeability of the BBB [67–69]. Increased BBB permeability and IL-6
levels within the brain were shown when systemic inflammation was induced by a
peripheral lipopolysaccharide injection to an Alzheimer’s APP transgenic mouse,
resulting in more severe cognitive symptoms [70]. Thus we speculate that the nature of
this [18F]FEPPA uptake and subsequent TSPO overexpression within the brain may be
due a result of a similar incidence. However, it should be noted that within a study
investigating the permeability of the BBB in mdx mice, CD4-, CD8-, CD20- and CD68positive cells were not histologically observed within the BBB perivascular stroma [71].
These observations, while contrasting, do not conflict with our findings as alternate
passages of cytokines through the BBB has already been extensively investigated [72,73].
A possible source of systemic inflammation/pro-inflammatory cytokines within our study
include the dystrophin-deficient cardiac and skeletal muscles—which as stated before are
known to sustain critical damage upon sarcolemma contraction and release proinflammatory cytokines into circulation. The concomitant TSPO-tracer uptake within
both the heart and brain and our autoradiography and biodistribution results (i.e. trends
towards heightened binding across almost all tissue types) speaks to the systemic nature
of inflammation within DMD, while hinting its possible contribution to both downstream
cardiac and neurodegeneration damage. It will be interesting to investigate if the
neuroinflammation observed in this DMD mice model is widespread across the whole
brain, or specific to certain regions, especially in the hippocampus where atrophy within
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this region has been linked to progressive cognitive impairment in DMD mice [12].
Further PET/MRI studies linking [18F]FEPPA PET to regional MRI volumetry and
functional MRI network changes will help shed more light.
The strengths of our study include: 1) the utility of non-invasive inflammation imaging
using second generation TSPO radioligand [18F]FEPPA, 2) the use of a high-resolution
(1.4 –1.5mm) small animal PET scanner capable of multi-organ/whole-body image data
acquisition, and 3) the showcase of tissue-specific dosimetry and molecular
colocalization capabilities via biodistribution and autoradiography respectively in a DMD
murine models—allowing for the additional in-vitro histopathological validation of our
in-vivo imaging studies. However, this study also has several limitations. Firstly, the
study sample size is relatively small and uses a mixed sex murine cohort despite DMD
being a X-linked genetic disorder and thus, primarily appearing in only human male
patients. While this is a common notion in DMD pre-clinical literature since both sexes
can express this phenotype through mutations in their dystrophic and utrophin genes,
there have been reports that female patients and rodents express constitutively higher
levels of TSPO in both cardiac and neural tissue [56,74–76]. Due to low sample sizes, we
could not account for these potential sex differences with this study; however, a fair
balance between sexes were used (wild-type: 2 females, 4 males; DMD: 2 females, 2
males). Secondly, similar to other TSPO-PET literature, [18F]FEPPA is unable to
differentiate between macrophage/microglia morphological states (i.e. pro-inflammatory
and anti-inflammatory). Lastly, while [18F]FEPPA is commonly used to assess activated
microglia, it is difficult to discern the true sensitivity of this tracer within DMD as TSPO
is also present in astrocytes, pericytes, and endothelial cells, among other structures
within the brain at low levels. During DMD, astrocytes may be activated due to a lack of
functional dystrophin, as its absence can precipitate a series of complex signalling
cascades that leads to glutamate toxicity in the CNS [77]. However, it should be noted
that the percentage of cells expressing TSPO are reported to be ~7 times higher for
microglia than for astrocytes, as measured by scRNA-seq—suggesting a preference for
the TSPO radiotracer to bind to microglia [78]. Thus, it is suggested that further multitracer studies using both [18F]FEPPA and specific PET tracers targeting solely activated
macrophages or microglia such as triggering receptor expressed on myeloid cells
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(TREM) can be used to further validate the use of [18F]FEPPA as a multi-organ
inflammation assessment tool in DMD [79].

2.5

Conclusions

This exploratory study demonstrated that dystrophin-deficient subjects were associated
with higher inflammatory [18F]FEPPA radiotracer binding, mirroring ex-vivo histological
TSPO data within both their hearts and their brains, and suggesting the presence of earlyonset cardiac- and neuroinflammation. Thus, TSPO-PET might be a useful tool for the invivo assessment of chronic inflammation in several organs simultaneously, particularly
within a dystrophic disease.
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Chapter 3
3

Conclusions and Future Directions

3.1

Study Summary

The aim of this thesis was to primarily explore the use of [18F]FEPPA PET for noninvasive imaging of in-vivo inflammatory involvement in the heart and brain of
mdx:utrn(+/-) mice. From this thesis, two main conclusions were reached: 1) the
dystrophic heart and brain are associated with significant inflammation, and 2)
[18F]FEPPA PET is able to assess multi-organ inflammatory load within murine models
of DMD.
We demonstrated that 8-10 week old mdx:utrn(+/-) mice had higher [18F]FEPPA uptake
in their heart and brains compared to age-matched healthy counterparts, which correlated
with heightened ex-vivo TSPO levels in our histological data. Preliminary
autoradiography and biodistribution also demonstrated the potential ex-vivo use of
[18F]FEPPA to assess inflammatory load within other organs—indicating the feasibility
of this imaging tool as a useful multi-organ assessment tool for inflammation as a result
of DMD.
The heightened [18F]FEPPA uptake in the dystrophic heart may be a result of activated
cardiac macrophage recruitment to regions of contraction-induced damage caused by
dystrophin-loss [1]. However, we speculate that since its onset is observed far earlier than
cardiac dysfunction (typically observed at 10 months of age in murine models), this early
inflammatory response may contribute to the downstream pathology of dystrophic
cardiac tissue damage. Similar incidences of heightened TSPO expression was also
observed within the dystrophic brain, which may be the result of microglial cells
activation. BBB disruption by a lack of dystrophin may be one of the driving causes, as
its increased permeability leads to pro-inflammatory cytokine infiltration [2–4]. As
activated microglia may act as both a source and target of inflammatory cytokines, it is
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possible that the cytokine-mediated cognitive impairment hypothesis within the
dystrophic brain can be mediated by activated microglia [3–6].

3.2

Significance

With increased DMD patient longevity, there have been growing concerns in identifying
and treating later onset of symptoms in other organs—specifically within the heart and
brain—associated with the later stages of DMD [7–9]. As inflammation is reputably
widespread within both dystrophic skeletal and cardiac muscle, and is becoming a
growing concern within the dystrophic brain, the subsequent development of antiinflammatory therapies that could be implemented prior to onset of severe cardiac or
neurological damage can be considered [1,3,10]. As such, the main significance of this
research lies in its contribution to the better understanding of inflammation—specifically
through providing a tool for researchers to better assess inflammatory load within
multiple dystrophic organs at once. The use of [18F]FEPPA imaging is novel, as this work
is the first to utilise a specific inflammatory PET tracer (TSPO) within mdx mice rather
than using the more conventional [18F]FDG (which have only been assessed in terms of
glucose consumption previously) [11–13]. Additionally, the use of PET in conjunction
with autoradiography and biodistribution within our study protocol is also significant. It
allows for assessment of inflammation on both an in-vivo (via non-invasive PET) and exvivo (via autoradiography and distribution) level within one specimen, while accounting
for potential inter-individual heterogeneity between subjects.
Using [18F]FEPPA, inflammation is seemingly observable in dystrophic cardiac tissue at
8-10 weeks of age, while signs of neuroinflammation were also present. The observations
of neuroinflammation as well as the concurrent presence of cardiac inflammation within
the dystrophic subject are novel, as they are the first to demonstrate significant TSPOupregulation within the dystrophic heart and brain—to which we attribute to activated
macrophages and microglia. From these data, the potential avenue of modulating
inflammation as a potential therapy is further emphasized.
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3.3

Limitations

Our findings within this thesis have profound impact in the field of DMD imaging
research. However, as with all studies, there exists some limitations. Firstly, although we
discussed our findings with a pro-inflammatory inclination, the inability of [18F]FEPPA
to differentiate between pro-inflammatory M1-like and anti-inflammatory M2-like
macrophages/microglial cells should be noted [14]. This has been an on-going concern
for multiple inflammatory PET analogues—including all the TSPO-PET tracer series as
well as the clinically used [18F]FDG. However, amongst a comparative study assessing
the inflammatory cell uptake of five candidate inflammation tracers in myocardium,
[18F]GE180—another TSPO-targeting PET tracer—showed preferential accumulations in
pro-inflammatory M1 macrophages that was seven-fold higher than in M2 [15]. In
addition, [18F]GE180 also showed highly selective binding to CD11b+ monocytes over
other cell types (i.e. T-cells, natural killer cells), further demonstrating the specificity of
TSPO-targeting radiotracers. Considering that [18F]GE180 has 20 times lowered brain
penetration than other TSPO tracers—including [18F]PBR28, which is very similar to
[18F]FEPPA—we can anticipate better specificity [16]. In addition, it should be noted that
in-vivo macrophages are not merely classified into M1 or M2 subclasses, but rather will
shift its phenotype on a spectrum towards a certain morphology depending on the signals
they receive. As such, it is quite possible for macrophages to display a mixed phenotype,
having both M1 and M2 characteristics [17,18]. Nonetheless, as the true aim of this was
to assess the ability of TSPO-PET to track multi-organ inflammatory load—in which it
does— this discrepancy does not take away from this conclusion.
Secondly, while we have used [18F]FEPPA within this study as an analog of activated
microglia within the brain, TSPO expression is known to come from several different
sources. For instance, TSPO is also constitutively expressed at low levels on astrocytes,
pericytes, endothelial cells, among other structures within the brain. These low-levels of
expression are not anticipated to cause a discrepancy to our drawn conclusions, as TSPO
is typically overexpressed at significantly higher levels under disease conditions.
However, it should be noted that reactive astrocytes are also known to overexpress TSPO
under certain conditions [19]. This is of concern within our DMD models, as the lack of
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dystrophin can trigger a signaling cascade that results in the inhibition of effective
glutamate clearance. As glutamate toxicity within the body can prompt astrocyte
activation, it is possible that the overexpressed TSPO levels (and subsequent [18F]FEPPA
uptake) within the dystrophic brain may not strictly reflect activated microglia [20,21].
However, within a study using scRNA-seq to assess TSPO expression within various
neuronal cell populations, the percentage of cells expressing TSPO were reported to be
~7 times higher for microglia than for astrocytes [22]. Thus, while TSPO expression
seems to skew towards microglia—thereby supporting our study conclusions—the
specificity of TSPO-radiotracer in targeting microglia should be considered in future
studies. This is similarly an issue within the heart, as TSPO is also overexpressed by
injured cardiomyocytes. Although its involvement is still unclear, the RNA knockout of
TSPO in cardiomyocytes post-anoxia/reoxygenation treatment (an analogue of
ischemic/reperfusion injury) resulted in inhibited mitochondrial ROS generation and
decreased apoptotic cell death [23]. Initially in this thesis, there was the intention of
validating the specificity of TSPO through histological co-staining with CD68 or
MHCII—which are commonly expressed on activated macrophages and microglia cells
[24,25]. Unfortunately, this was not accomplished due to restraints imposed by current
global events, but future work in this capacity is suggested to validate the specific
contribution of glial cells to DMD cardiac and neurologic outcomes.
Lastly within this thesis, both male and female murine models were used. Despite DMD
being more prominently featured in males since it is an X-linked recessive genetic
disorder, both sexes exhibit DMD pathogenesis due to mutations in dystrophin and
utrophin genes. This is commonplace within DMD literature, as several studies
(including our own) use a mixed sex cohort during experimentation [26–28]. However,
within an acute myocarditis study, females were reported to constitutively express higher
levels of TSPO within cardiac tissue than males prior to disease onset [29]. Similarly,
healthy female patients were found to have higher [11C]PBR28 binding across global grey
matter, frontal, temporal, occipital and parietal cortices, hippocampus, and thalamus than
their males counterparts [30]. Due to low sample sizes, we could not account for sex as a
covariate within our statistical analyses; however, a fair balance between sexes were used
(wild-type: 2 females, 4 males; DMD: 2 females, 2 males). Nonetheless, future
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investigation towards determining the baseline TSPO levels within cardiac and neural
tissue of dystrophic subjects is advised.

3.4

Future Directions

The work of this thesis has demonstrated the feasibility of [18F]FEPPA PET as a noninvasive tool to assess multi-organ inflammatory involvement in-vivo and investigated
the presence of inflammatory load within the dystrophic heart and brain of mdx:utrn(+/-)
mice. While the conclusions drawn are useful to the field of inflammatory imaging as
well as to DMD research in general, there are still additional questions to be answered.
We demonstrated the presence of immune cells within the dystrophic heart and brain
histologically and with PET imaging. A future area of interest is in the pairing of our
imaging protocol with an additional modality (e.g. MRI or CT) to discern the presence of
any anatomical or functional outcomes associated with or co-localized to inflammatory
involvement. Histologically, in the DMD heart, inflammatory foci concentrate to regions
of cardiac damage (i.e. tissue necrosis, fibrosis, lesions) [31]. While, some DMD boys
have indicated signs of brain atrophy in some computed tomography (CT) and MRI scans
[32,33]. As such, these future studies may be useful in delineating the contribution of
activated macrophages and microglia to dystrophic cardiac and neurological
morphological outcomes.
As one of the major benefits of our imaging protocol is its in-vivo and minimally invasive
nature, another future direction is the longitudinal imaging of inflammation throughout
disease progression. Within this exploratory study, we have demonstrated the possible
presence of inflammatory cells in DMD mice at the 8-10 week time point, despite mdx
mice studies reporting cardiomyopathy symptoms and cognitive degeneration at 10 and
18 months respectively [9,34]. Thus, a study longitudinally imaging mdx mice at 4-5
weeks (immature), 8-10 weeks, 15-20 weeks (matured), and ~10 months (aged) should be
conducted to gain a better understanding of inflammation throughout age progression.
Our [18F]FEPPA PET protocol can also be applied to different mdx mouse models—
genetically mutated to demonstrate different disease severities—for a greater
understanding of disease progression [28,34]. In addition, this protocol may also be
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performed in conjunction with echocardiograms or various forms of cognitive tests to
assess inflammation in relation to the emergence/evolution of DMD cardiac and
neurologic functional outcomes.
Lastly, although our sample size for the biodistribution and autoradiography analyses are
admittedly small, its trends (in combination with our PET and histological data)
demonstrate the feasibility of an in-vivo to ex-vivo protocol that can be used to
systematically image inflammation. In addition to DMD, there are many other
inflammation-associated diseases that yield multi-organ dysfunction such as: multiple
sclerosis, rheumatoid arthritis, cardiovascular diseases, etc. [35–37]. Thus, there are
several diseases that can utilise this [18F]FEPPA imaging protocol for a more systemic
understanding of inflammation within several organs simultaneously on both an in-vivo
(via non-invasive PET) as well as ex-vivo (via autoradiography and biodistribution) level.

3.5

Concluding Remarks

In conclusion, the results of this thesis suggest that [18F]FEPPA PET may be a feasible
tool to assess in-vivo inflammatory load within multiple dystrophic organs
simultaneously. Using this imaging tool, we have demonstrated that dystrophin-deficient
mice have heightened levels of activated macrophages and microglia within their hearts
and brains respectively—thereby supporting our hypothesis. While it is evident that
inflammation is present within the cardiac and neural tissue of DMD subjects, further
research is necessary to better understand the contribution of activated immune cells to
the dysfunctional outcomes. We anticipate that [18F]FEPPA imaging may be useful in
these endeavors.
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Appendix B: Quantitative autoradiography and Biodistribution of
[18F]FEPPA-injected 8-10 week old mdx:utrn (+/-) mice.
The following data were submitted as Supplementary Material in the following
manuscript:
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy:
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under
Review. Manuscript ID: NWD-S-20-00539.

Figure. A.1. Multi-organ Biodistribution of [18F]FEPPA within murine models. Data
(±SE) shows the differences in radiotracer uptake as across multiple tissues as the
percentage of the injected dose per gram of the tissue (%ID/g) of DMD (black bars; n=4
mice) and age-matched healthy controls (white bars; n=2 mice). No statistical analyses
were conducted due to low sample sizes. DMD=Duchenne muscular dystrophy,
[18F]FEPPA=[18F]-N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide.
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Figure A.2. Quantified autoradiography of [18F]FEPPA activity in DMD and healthy
mice. Data (±SE) depicts the log counts per second per millimetre squared area of
[18F]FEPPA activity within slices of heart, brain, thoracic aorta, diaphragm, skeletal
muscles, kidney and liver for DMD (black bars; n=3 mice) and an age-matched wild-type
control (white bars; n=1 mouse). No statistical analyses were conducted due to low
sample sizes. Abbreviations as described in prior figures.

Appendix C: Sample sizes for imaging and histologic studies
The following data were also submitted as Supplementary Material in the following
manuscript:
Tang JM, McClennan A, Liu L, Hadway J, Ronald J, Hicks JW, Hoffman L, Anazodo
UC. In-vivo imaging of cardiac and neuroinflammation in Duchenne muscular dystrophy:
a [18F]FEPPA PET study. Submitted to Neuromuscul Disord in August 2020. Under
Review. Manuscript ID: NWD-S-20-00539.

73

Table A.1. Sample size for the number of unique wild-type and DMD murine subjects
were successfully completed for each imaging and histological cohort.
PET Biodistribution Autoradiography Immunohistochemistry
Wild-type
C57Bl10
DMD
mdx:utrn(+/-)

6

2*

1

3

4

4*

3

3

* indicates the removal of impossible biodistribution values for which measurement
errors resulted in negative results (i.e. negative tissue weights stemming from weight of
empty tube exceeding the weight of tube&tissue)

Appendix D: Representative qualitative autoradiography images from
[18F]FEPPA-injected 8-10 week old mdx:utrn (+/-) mice

Image depicts autoradiography images of the heart, brain, thoracic aorta, diaphragm,
gastrocnemius, tibialis anterior, kidney, and liver tissue excised from [18F]FEPPAinjected murine models. The representative DMD mouse depicts higher tracer
accumulation across all tissue compared to the healthy wild-type control. Regions of
tissue are outlined in red. LU=light units.
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Appendix E: Copyright Agreement for reproduction of Figure
1.1
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